Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis

American Journal Geriatric Pharmacotherapy

Volumn 4, Issue 1, 2006, Pages 14-24

  Wagg, Adrian ^a   Wyndaele, Jean Jacque ^b   Sieber, Paul ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Urological Associates of Lancaster   (United States)

Author keywords

elderly; overactive bladder syndrome; retrospective analysis; solifenacin; urinary incontinence

Indexed keywords

PLACEBO; SOLIFENACIN;

AGING; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINENCE; DATA ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFORMATION PROCESSING; MEDICAL RECORD; META ANALYSIS; MICTURITION; NOCTURIA; OVERACTIVE BLADDER; PREVALENCE; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; XEROSTOMIA;

AGED; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SYNDROME; TETRAHYDROISOQUINOLINES; URINARY INCONTINENCE;

EID: 33646770677     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2006.03.004     Document Type: Article

References (30)

1. Abrams P., Cardozo L., Pall M., et al., Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
2. Ouslander J.G. Management of overactive bladder. N Engl J Med 350 (2004) 786-799
3. Stewart W.P., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 (2003) 327-336
4. Wagg A., and Cohen M. Medical therapy for the overactive bladder in the elderly. Age Ageing 31 (2002) 241-246
5. Wagner T.H., Hu T.W., Bentkover J., et al. Health-related consequences of overactive bladder. Am J Manag Care 8 Suppl 19 (2002) S598-S607
6. Brown J.S., McGhan W.P., and Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 6 Suppl 11 (2000) S574-S579
7. Abrams P., Kelleher C.J., Kerr L.A., and Rogers R.G. Overactive bladder significantly affects quality of life. Am J Manag Care 6 Suppl 11 (2000) S580-S590
8. Coyne K.S., Payne C., Bhattacharyya S.K., et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: Results from a national community survey. Value Health 7 (2004) 455-463
9. Serels S. The wet patient: Understanding patients with overactive bladder and incontinence. Curr Med Res Opin 20 (2004) 791-801
10. Hu T.W., and Wagner T.H. Economic considerations in overactive bladder. Am J Manag Care 6 Suppl 11 (2000) S591-S598
11. Thom D.H., Haan M.N., and Van Den Eeden S.K. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing 26 (1997) 367-374
12. Andersson K.E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3 (2004) 46-53
13. Ruoff G.E. Challenges of managing chronic pain in the elderly. Semin Arthritis Rheum 32 Suppl 1 (2002) 43-50
14. Kay G.C., and Granville L.J. Antimuscarinic agents: Implications and concerns in the management of overactive bladder in the elderly. Clin Ther 27 (2005) 127-140
15. Katz I.R., Sands L.P., Bilker W., et al. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc 46 (1998) 8-13
16. Tsao J.W., and Heilman K.M. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 349 (2003) 2274-2275
17. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172 (2004) 1919-1924
18. Chapple C.R., Rechberger T., Al-Shukri S., et al., YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93 (2004) 303-310
19. Brunton S., and Kuritzky L. Recent developments in the management of overactive bladder: Focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 21 (2005) 71-80
20. Haab F., Cardozo L., Chapple C., Ridder A.M., and Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47 (2005) 376-384
21. Available at:. The European Agency for the Evaluation of Medicinal Products. Accessed. ICH Topic E 6: Guideline for Good Clinical Practice (February 28, 2006). http://www.emea.eu.int/pdfs/human/ich/013595en.pdf
22. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 284 (2000) 3043-3045
23. van Elteren P.H. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 37 (1960) 351-361
24. Krauwinkel W.J., Smulders R.A., Mulder H., et al. Effect on age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 43 (2005) 227-238
25. VESIcare (2004), Yamanouchi Pharma America, Inc., and The GlaxoSmithKline Group of Companies, Paramus, NJ and Research Triangle Park, NC
26. Ko Y., Lin S.J., Salmon J.W., and Bron M.S. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 11 Suppl 4 (2005) S103-S111
27. Loesche W.J., Bromberg J., Terpenning M.S., et al. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. J Am Geriatr Soc 43 (1995) 401-407
28. Ouslander J.G., Shih Y.T., Malone-Lee J., and Luber K. Overactive bladder: Special considerations in the geriatric population. Am J Manag Care 6 Suppl 11 (2000) S599-S606
29. Shaya F.T., Blume S., Gu A., et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11 Suppl 4 (2005) S121-S129
30. Kelleher C.J., Cardozo L.D., Khullar V., and Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104 (1997) 988-993